Abstract Library

#4471 Acromegaly and small intestinal neuroendocrine tumours: Association or coincidence?

Introduction: Neuroendocrine tumours of the small intestine (SI-NETs), although rare, are the most prevalent primary neoplasms of this organ. Acromegaly is characterised by excessive secretion of growth hormone (GH), typically due to a pituitary adenoma, but in rare cases, it can result from ectopic secretion of GH-releasing hormone (GHRH) by non-pituitary tumours, particularly NETs of the lung or pancreas.

Conference:

Presenting Author: G. Martins R

Authors: Martins Fernandes A, Silva L, Serranito M, Elvas A, Santos J,

Keywords: neuroendocrine tumour, small intestinal neuroendocrine tumour, acromegaly,

#4385 SDHB-related metastatic paragangliomas treated with capecitabine and temozolomide: Experience of a tertiary centre

Introduction: SDHB pathogenic variants predispose to aggressive and metastatic paragangliomas (mPGLs). International consensus recommends temozolomide treatment (low-grade evidence). Capecitabine and temozolomide (CAPTEM) has shown advantage over temozolomide in the treatment of neuroendocrine tumours (NETs). Evidence for its use in mPGLs remains scarce.

Conference:

Presenting Author: G. Martins R

Authors: Silva L, Martins R, Couto J, Garcia R, Martins Fernandes A,

Keywords: mPGL, SDHB, captem,

#4162 Functioning neuroendocrine neoplasms: Symptomatic control with 177Lu-DOTATATE

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is recommended in unresectable and metastatic gastroenteropancreatic neuroendocrine neoplasms (NENs), however, recommendations for functioning NENs (F-NENs) are not well established. Besides PRRT impact in OS and PFS, real-life benefit in clinical control is also a relevant outcome, especially in F-NENs.

Conference:

Presenting Author: Santos A

Authors: Lopes-Pinto M, Silva D, Ribeiro S, Oliveira J, Ferreira G,

Keywords: neuroendocrine neoplasm, functioning neuroendocrine neoplasm, carcinoid syndrome, PRRT,

#3915 Real world data of CAPTEM in metastatic neuroendocrine tumors

Introduction: Neuroendocrine tumors (NET) are commonly treated with multimodality therapy.

Conference:

Presenting Author:

Authors: Ramos M, Barbosa A, Azevedo I, Rodrigues A, Silva J,

Keywords: CAPTEM, NET, Real-world data,

#3571 A multicentric randomized phase II trial of CAPTEM (CT) or Folfiri (F) as second-line therapy in neuroendocrine carcinomas (NEC) and exploratory analysis of predictive role of PET imaging and biological markers (SENECA Study)

Introduction: No standard 2nd line treatment has been validated in patients (pts) with metastatic or locally advanced, non-resectable, grade 3 gastroenteropancreatic (GEP) and lung NEC after first-line platinum therapy. Furthemore more accurate prognostic biomarkers are needed.

Conference:

Presenting Author: Bongiovanni A

Authors: Bongiovanni A, Foca F, Bergamo F, Leo S, Pusceddu S,

Keywords: neuroendocrine carcinoma, FOLFIRI, CAPTEM, second line, Phase 2, NEC, Temozolomide, Capecitabine,